login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
USA Market Overview
Canada Market Overview
Europe Market Overview
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Swing Trading Course
Account
Disclaimer
Affiliate
Contact
Privacy
SPERO THERAPEUTICS INC (SPRO) Stock News
USA
- NASDAQ:SPRO -
US84833T1034
-
Common Stock
2.25
USD
-0.11 (-4.66%)
Last: 10/10/2025, 5:20:02 PM
2.1799
USD
-0.07 (-3.12%)
After Hours:
10/10/2025, 5:20:02 PM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
SPRO Latest News, Press Relases and Analysis
All
Press Releases
2 months ago - By: Zacks Investment Research
Down 17.7% in 4 Weeks, Here's Why Spero Therapeutics (SPRO) Looks Ripe for a Turnaround
2 months ago - By: Benzinga
- Mentions:
SBFM
AZTA
DERM
XAIR
...
12 Health Care Stocks Moving In Tuesday's After-Market Session
2 months ago - By: Spero Therapeutics, Inc.
Spero Therapeutics Announces Second Quarter 2025 Operating Results and Provides a Business Update
2 months ago - By: Benzinga
Earnings Outlook For Spero Therapeutics
2 months ago - By: Spero Therapeutics, Inc.
Spero Therapeutics to Report Second Quarter 2025 Financial Results and Provide Business Update on Tuesday, August 12, 2025
4 months ago - By: Yahoo Finance
- Mentions:
DHI
CMG
Spero Therapeutics Jumps as Oral Carbapenem Hits Phase 3 Milestone
4 months ago - By: Zacks Investment Research
- Mentions:
GSK
AGEN
ADPT
SPRO Stock Soars 245% on GSK-Partnered UTI Drug Meeting Study Goal
5 months ago - By: Stocktwits
- Mentions:
GSK
VTI
GSK, Spero Therapeutics Stop Antibiotic Trial For Complicated Urinary Tract Infections Early After Positive Results, Retail’s Thrilled
5 months ago - By: Bloomberg
GSK Stops Antibiotic Trial Early After Seeing Positive Results
5 months ago - By: Spero Therapeutics, Inc.
Spero Therapeutics Announces First Quarter 2025 Operating Results and Provides a Business Update
5 months ago - By: Zacks Investment Research
- Mentions:
QURE
UniQure (QURE) Reports Q1 Loss, Misses Revenue Estimates
5 months ago - By: Zacks Investment Research
- Mentions:
RNA
Avidity Biosciences, Inc. (RNA) Reports Q1 Loss, Misses Revenue Estimates
5 months ago - By: Zacks Investment Research
- Mentions:
MIRM
Mirum Pharmaceuticals, Inc. (MIRM) Reports Q1 Loss, Tops Revenue Estimates
6 months ago - By: Spero Therapeutics, Inc.
Spero Therapeutics Appoints Esther Rajavelu as President and Chief Executive Officer
7 months ago - By: Zacks Investment Research
- Mentions:
NRIX
Spero Therapeutics, Inc. (SPRO) Reports Q4 Loss, Tops Revenue Estimates
7 months ago - By: Spero Therapeutics, Inc.
Spero Therapeutics Announces Fourth Quarter and Full Year 2024 Operating Results and Provides a Business Update
8 months ago - By: Spero Therapeutics, Inc.
UPDATE – Spero Therapeutics to Present at TD Cowen 45th Annual Health Care Conference
9 months ago - By: Spero Therapeutics, Inc.
Spero Therapeutics Provides Business Update and Announces Interim Leadership Changes
Please enable JavaScript to continue using this application.